Heteroaromatic Compounds Modulating Dopamine D1 Receptors
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current pharmaceutical agents are inadequate in effectively modulating dopamine D1 receptors, which are implicated in various neurological and psychiatric disorders, necessitating the development of new compounds that can agonize or partially agonize D1 receptors to treat associated disorders.
Innovation Solution
A method involving the administration of a therapeutically effective amount of a compound of Formula I or its pharmaceutically acceptable salt, which includes specific heteroaryl or heterocycloalkyl moieties, to modulate D1 receptors, thereby treating D1-mediated disorders such as schizophrenia, ADHD, and other conditions.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If current pharmaceutical agents are used, then treatment of D1-mediated disorders is provided, but the agents are inadequate in effectively modulating dopamine D1 receptors
Solution Approach 1:
The patent applies parameter changes by modifying the chemical structure of dopamine receptor ligands through systematic variation of substituents at specific positions (R1-R6, R8-R12) on the core heterocyclic framework. This enables tuning of pharmacological properties including agonist/partial agonist activity at D1 receptors, thereby improving effectiveness while maintaining adaptability to different D1-mediated disorder requirements
Solution Approach 2:
The patent creates a universal platform of compounds with core structure I that can function as D1 agonists, partial agonists, or antagonists depending on substituent configuration. This multi-functional design allows a single compound series to address various D1-mediated disorders (schizophrenia, ADHD, Parkinson's disease, depression) with different pathophysiological mechanisms, thereby resolving the contradiction between reliability and adaptability
2Reliability
If new compounds are developed to effectively modulate D1 receptors, then therapeutic benefits for D1-mediated disorders are achieved, but the complexity of compound design and synthesis increases
Solution Approach 1:
The patent segments the molecule into distinct functional domains: a core heterocyclic scaffold (structures I-VI) that provides the D1 receptor binding framework, and variable substituent groups (R1-R12) that fine-tune pharmacological activity. This segmentation allows systematic optimization of therapeutic efficacy while maintaining a manageable structural foundation, reducing the perceived complexity through modular design
Solution Approach 2:
The patent applies local quality by introducing specific substituent groups at defined positions on the core structure to achieve desired pharmacological properties. For example, particular substituents at R3-R6 positions enhance D1 agonist activity, while others modify selectivity or pharmacokinetic properties. This localized modification approach enables precise control of therapeutic efficacy without requiring complete structural redesign, thereby managing complexity
Data Source
AI summary
The present invention provides, in part, compounds of Formula I:and pharmaceutically acceptable salts thereof; processes for the preparation of; intermediates used in the preparation of; and compositions containing such compounds or salts, and their uses for treating D1-mediated (or D1-associated) disorders including, e.g., schizophrenia (e.g., its cognitive and negative symptoms), schizotypal personality disorder, cognitive impairment (e.g., cognitive impairment associated with schizophrenia, AD, PD, or pharmacotherapy therapy), ADHD, Parkinson's disease, anxiety, and depression.